Trailing-twelve-month (TTM) revenue is $14.74 Billion with a year-over-year growth of +4.40%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,759,900,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $3,703,600,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $3,517,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $3,756,800,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $14,737,300,000 |
Current P/S: $19,739,167,485 market capitalization ÷ $14,737,300,000 TTM revenue = 1.34x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $3.76B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-19T00:16:05.757Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Brands | $5.2B | $10.8B | $9.9B | $9.8B | $9.2B | $9.2B |
| Complex GX and Biosimilars | $1.3B | $1.3B | $1.3B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Developed Markets Segment | $8.5B | $10.4B | $9.8B | $9.3B | $9.0B | $8.6B |
| Emerging Markets Segment | $1.9B | $3.1B | $2.6B |
$14.74B
$14.74 Billion
+4.40%
vs. $14.12B a year ago (TTM)
+3.66%
5 Year compound annual growth rate
1 Year
+4.40%
3 Year
(1.88%)
5 Year
+3.66%
10 Year
+4.02%
15 Year
+6.64%
20 Year
+12.45%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $14.30B | ($439.40M) | (2.98%) |
| 2024 | $14.74B | ($687.60M) | (4.46%) |
| 2023 | $15.43B | ($835.80M) | (5.14%) |
| 2022 | $16.26B | ($1.62B) | (9.08%) |
| 2021 | $17.89B | +$5.94B | +49.73% |
| 2020 |
TTM Growth
+4.40%
3-Year CAGR
(1.88%)
5-Year CAGR
(1.14%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-19T00:16:05.757Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| Generics | $5.3B | $5.6B | $5.0B | $5.6B | $5.5B | $5.1B |
|---|
| $2.3B |
| $2.2B |
| Greater China Segment | $260M | $2.2B | $2.2B | $2.2B | $2.2B | $2.3B |
|---|
| Japan, Australia and New Zealand Segment | $1.2B | $2.0B | $1.6B | $1.4B | $1.3B | $1.2B |
|---|
| $11.95B |
| +$445.50M |
| +3.87% |
| 2019 | $11.50B | +$66.60M | +0.58% |
| 2018 | $11.43B | ($473.80M) | (3.98%) |
| 2017 | $11.91B | +$830.80M | +7.50% |
| 2016 | $11.08B | +$1.65B | +17.47% |
